WT1 HLA class II-binding peptides and compositions and methods comprising same

Patent metadata

Field	Value
Publication number	US-11548924-B2
Application number	US-201916270444-A
Country	US
Kind code	B2
Filing date	Feb 7, 2019
Priority date	Oct 17, 2005
Publication date	Jan 10, 2023
Grant date	Jan 10, 2023

Abstract

This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.

First claim

What is claimed is:

1. An isolated Wilms' tumor 1 (WT1) peptide linked to another molecule, wherein the peptide consists of the amino acid sequence RSDELVRHHNMHQRNMTKL (SEQ ID NO: 2), or
an isolated W I 1 peptide linked to another molecule, wherein the peptide consists of the amino acid sequence PGCNKRYFKLSHLQMHSRKHTG (SEQ ID NO: 4), or
the combination of an isolated WT1 peptide linked to another molecule, wherein the peptide consists of the amino acid sequence RSDELVRHHNMHQRNMTKL (SEQ ID NO: 2), and an isolated WT1 peptide linked to another molecule, wherein the peptide consists of the amino acid sequence PGCNKRYFKLSHLQMHSRKHTG (SEQ ID NO: 4).

2. The isolated WT1 peptide linked to another molecule of claim 1 wherein the molecule linked to the WT1 peptide is an immunomodulating compound.

3. The isolated WT1 peptide linked to another molecule of claim 2 wherein the immunomodulating compound is a cytokine, chemokine, or complement component that enhances expression of immune system accessory or adhesion molecules, their receptors, or combinations thereof.

4. The isolated WT1 peptide linked to another molecule of claim 2 wherein the immunomodulating compound is an interleukin, interferon alpha, beta or gamma, tumour necrosis factor, granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), granulocyte colony stimulating factor (G-CSF), a chemokine, a complement component, or combinations thereof.

5. The isolated WT1 peptide linked to another molecule of claim 2 wherein the immunomodulating compound stimulates expression, or enhances expression of OX40, OX40L (gp34), lymphotactin, CD40, CD40L, B7.1, B7.2, TRAP, ICAM-2, ICAM-3, cytokine receptors, CD28, CTLA-4, a B7 molecule, a heat stable antigen (HSA), chondroitin sulfate-modified MHC invariant chain (Ii-CS), or an intracellular adhesion molecule 1 (ICAM-1), or combinations thereof.

6. The combination of the isolated WT 1 peptide linked to another molecule of claim 1 , wherein the peptide consists of the peptide having the amino acid sequence PGCNKRYFKLSHLQMHSRKHTG (SEQ ID NO: 4), and the isolated WT1 peptide linked to another molecule, wherein the peptide consists of the peptide having the amino acid sequence RSDELVRHHNMHQRNMTKL (SEQ ID NO: 2).

7. The combination of claim 6 , further comprising an isolated WT1 peptide linked to another molecule wherein the peptide consists of the peptide having the amino acid sequence YMFPNAPYL (SEQ ID NO:6).

8. A composition comprising the isolated WT1 peptide linked to another molecule of claim 1 , and an immunomodulating compound.

9. The composition of claim 8 wherein the immunomodulating compound is a cytokine, chemokine, or complement component that enhances expression of immune system accessory or adhesion molecules, their receptors, or combinations thereof.

10. The composition of claim 8 wherein the immunomodulating compound is an interleukin, interferon alpha, beta or gamma, tumour necrosis factor, granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), granulocyte colony stimulating factor (G-CSF), a chemokine, a complement component, or combinations thereof.

11. The composition of claim 8 wherein the immunomodulating compound stimulates expression, or enhances expression of OX40, OX40L (gp34), lymphotactin, CD40, CD40L, B7.1, B7.2, TRAP, ICAM-2, ICAM-3, cytokine receptors, CD28, CTLA-4, a B7 molecule, a heat stable antigen (HSA), chondroitin sulfate-modified MHC invariant chain (Ii-CS), or an intracellular adhesion molecule 1 (ICAM-1), or combinations thereof.

12. The isolated WT1 peptide linked to another molecule of claim 1 , wherein the molecule linked to the WT1 peptide is a protein or a polypeptide.

13. The isolated WT1 peptide linked to another molecule of claim 1 , wherein the WT1 peptide linked to another molecule is by a peptide bond, an ester or an ether.

14. The isolated WT1 peptide linked to another molecule of claim 1 , wherein the WT1 peptide is linked to the molecule through a homo-bifunctional agent or a hetero-bifunctional agent.

15. An isolated WT1 peptide linked to another molecule, wherein the peptide comprises the peptide having the amino acid sequence PGCNKRYFKLSHLQMHSRKHTG (SEQ ID No: 4) and the peptide having the amino acid sequence RSDELVRHHNMHQRNMTKL (SEQ ID No: 2), and further comprises a peptide having the amino acid sequence YMFPNAPYL (SEQ ID NO:6).

16. The isolated WT1 peptide linked to another molecule of claim 15 , wherein the molecule linked to the WT1 peptide is a protein or a polypeptide.

17. The isolated WT1 peptide linked to another molecule of claim 15 , wherein the molecule linked to the WT1 peptide is an immunomodulating compound.

Assignees

• Memorial Sloan Kettering Cancer Center

Inventors

• Scheinberg David
• Pinilla-Ibarz Javier
• May Rena

Classifications

• A61K2039/57

  characterised by the type of response, e.g. Th1, Th2 · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K14/4748 Primary

  Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P37/04

  Immunostimulants · CPC title